LONDON, May 17, 2017 /PRNewswire/ --
The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 145-page report you will receive 100 charts - all unavailable elsewhere.
The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Anti-Epilepsy Drugs Market forecasts from 2017-2027
• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets: - First-generation Drugs - Second-generation Drugs - Third-generation Drugs - Others
• This report also discusses the leading anti-epilepsy drugs: - Vimpat - Keppra - Briviact - Lamictal - Potiga/Trobalt - Lyrica - Neurontin
• Our analyses show individual revenue forecasts to 2027 for these regional markets: - US - Japan - EU5 - BRIC - RoW
• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK
• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market
• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy
• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market
• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016
Visiongain's study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.
Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.
To see a report overview please email Sara Peerun on [email protected]
List of Companies and Organizations Mentioned in the Report
Abide Therapeutics
Advicenne Pharma SA
Alexza Pharmaceuticals
American Epilepsy Society
Argentum Pharmaceuticals
Biscayne Neurotherapeutics
Canadian Agency for Drugs and Technologies in Health (CADTH)
Catalyst Pharmaceuticals
Centers for Disease Control (CDC)
Eisai
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GlaxoSmithKline (GSK)
Grifols S.A.
GW Pharmaceuticals
International League Against Epilepsy (ILAE)
Italian Medicines Agency (AIFA)
Janssen Pharmaceuticals
Japanese Ministry of Health, Labour and Welfare (MHLW)
Marinus Pharmaceuticals
National Institute of Neurological Disorders and Stroke
Novartis
Otsuka Pharmaceuticals
Pfizer
Pharmaceutical Benefits Advisory Committee (PBAC)
Proximagen
PTC Therapeutics
Roche
Sage Therapeutics
Sanofi
Scottish Medicines Consortium (SMC)
SK Biopharmaceuticals
Takeda
The National Institute for Health and Care Excellence (NICE)
UCB
Upsher-Smith Laboratories
World Health Organization (WHO)
Zogenix
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1869/Global-Anti-Epilepsy-Drugs-Market-Forecast-2017-2027
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
Advertisement
First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin
Advertisement
The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 145-page report you will receive 100 charts - all unavailable elsewhere.
The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Anti-Epilepsy Drugs Market forecasts from 2017-2027
• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets: - First-generation Drugs - Second-generation Drugs - Third-generation Drugs - Others
• This report also discusses the leading anti-epilepsy drugs: - Vimpat - Keppra - Briviact - Lamictal - Potiga/Trobalt - Lyrica - Neurontin
• Our analyses show individual revenue forecasts to 2027 for these regional markets: - US - Japan - EU5 - BRIC - RoW
• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK
• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market
• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy
• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market
• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016
Visiongain's study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.
Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.
To see a report overview please email Sara Peerun on [email protected]
List of Companies and Organizations Mentioned in the Report
Abide Therapeutics
Advicenne Pharma SA
Alexza Pharmaceuticals
American Epilepsy Society
Argentum Pharmaceuticals
Biscayne Neurotherapeutics
Canadian Agency for Drugs and Technologies in Health (CADTH)
Catalyst Pharmaceuticals
Centers for Disease Control (CDC)
Eisai
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GlaxoSmithKline (GSK)
Grifols S.A.
GW Pharmaceuticals
International League Against Epilepsy (ILAE)
Italian Medicines Agency (AIFA)
Janssen Pharmaceuticals
Japanese Ministry of Health, Labour and Welfare (MHLW)
Marinus Pharmaceuticals
National Institute of Neurological Disorders and Stroke
Novartis
Otsuka Pharmaceuticals
Pfizer
Pharmaceutical Benefits Advisory Committee (PBAC)
Proximagen
PTC Therapeutics
Roche
Sage Therapeutics
Sanofi
Scottish Medicines Consortium (SMC)
SK Biopharmaceuticals
Takeda
The National Institute for Health and Care Excellence (NICE)
UCB
Upsher-Smith Laboratories
World Health Organization (WHO)
Zogenix
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1869/Global-Anti-Epilepsy-Drugs-Market-Forecast-2017-2027
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
